Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology - Université de Lorraine Accéder directement au contenu
Article Dans Une Revue European Journal of Heart Failure Année : 2019

Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology

1 UMCG - University Medical Center Groningen [Groningen]
2 UA - University of Antwerp
3 MHH - Medizinische Hochschule Hannover = Hannover Medical School
4 University of Glasgow
5 CIMA - Center for Applied Medical Research [Plamplona]
6 Clínica Universidad de Navarra [Pamplona]
7 Baker Heart and Diabetes Institute (AUSTRALIA)
8 Galecto Biotech AB [Gothenburg]
9 Charité Campus Virchow-Klinikum (CVK)
10 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
11 FibroGen Inc.
12 KCH - King's College Hospital
13 UPNA - Universidad Pública de Navarra [Espagne] = Public University of Navarra
14 IdiSNA - Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra
15 UiO - University of Oslo
16 Oslo University Hospital [Oslo]
17 Royal Brompton Hospital
18 Orion Pharma
19 University of Naples Federico II = Università degli studi di Napoli Federico II
20 King‘s College London
21 University Medical Center [Utrecht]
22 IMTTS - Institute of Molecular and Translational Therapeutic Strategies
23 DZHK - German Center for Cardiovascular Research
24 CIC-P - Centre d'investigation clinique plurithématique Pierre Drouin [Nancy]
25 DCAC - Défaillance Cardiovasculaire Aiguë et Chronique
26 INI-CRCT - Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy]
27 Cardiovascular & Renal Clinical Trialists - CRCT - French-Clinical Research Infrastructure Network - F-CRIN [Paris]
28 UMG - University Medical Center Göttingen
29 University hospital of Zurich [Zurich]
30 “Attikon” University Hospital
31 UMMC - University of Mississippi Medical Center
32 JMU - Julius-Maximilians-Universität Würzburg
33 University Hospital Wuerzburg / Universitäts­klinikum Würzburg
34 Maastricht University [Maastricht]
35 KU Leuven - Catholic University of Leuven = Katholieke Universiteit Leuven
36 The Netherlands Heart Institute
Kenneth E Lipson
  • Fonction : Auteur
Piero Pollesello
  • Fonction : Auteur

Résumé

Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each with different fibrosis subtypes and a different composition of various cells and proteins - resulting in a very complex pathophysiology. As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation, but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the mechanisms and the caveats and proposes a roadmap for future research.
Fichier principal
Vignette du fichier
European J of Heart Fail - 2019 - de Boer - Towards better definition quantification and treatment of fibrosis in heart.pdf (2.55 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03764243 , version 1 (30-08-2022)

Identifiants

Citer

Rudolf A de Boer, Gilles de Keulenaer, Johann Bauersachs, Dirk Brutsaert, John G Cleland, et al.. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21 (3), pp.272-285. ⟨10.1002/ejhf.1406⟩. ⟨hal-03764243⟩
21 Consultations
38 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More